VEREGEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Veregen, and what generic alternatives are available?
Veregen is a drug marketed by Ani Pharms and is included in one NDA. There are two patents protecting this drug.
This drug has thirty-one patent family members in twenty countries.
The generic ingredient in VEREGEN is sinecatechins. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the sinecatechins profile page.
DrugPatentWatch® Generic Entry Outlook for Veregen
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 2, 2026. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VEREGEN?
- What are the global sales for VEREGEN?
- What is Average Wholesale Price for VEREGEN?
Summary for VEREGEN
International Patents: | 31 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 8 |
Drug Prices: | Drug price information for VEREGEN |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VEREGEN |
What excipients (inactive ingredients) are in VEREGEN? | VEREGEN excipients list |
DailyMed Link: | VEREGEN at DailyMed |



DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VEREGEN
Generic Entry Date for VEREGEN*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
OINTMENT;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VEREGEN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Phase 2 |
ECOG-ACRIN Cancer Research Group | Phase 2 |
GTO Pharmaceutical, LLC | Phase 2 |
US Patents and Regulatory Information for VEREGEN
VEREGEN is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VEREGEN is ⤷ Try for Free.
This potential generic entry date is based on patent 5,795,911.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ani Pharms | VEREGEN | sinecatechins | OINTMENT;TOPICAL | 021902-001 | Oct 31, 2006 | RX | Yes | Yes | 7,858,662 | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Ani Pharms | VEREGEN | sinecatechins | OINTMENT;TOPICAL | 021902-001 | Oct 31, 2006 | RX | Yes | Yes | 9,770,406 | ⤷ Try for Free | Y | ⤷ Try for Free | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VEREGEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ani Pharms | VEREGEN | sinecatechins | OINTMENT;TOPICAL | 021902-001 | Oct 31, 2006 | 10,434,059 | ⤷ Try for Free |
Ani Pharms | VEREGEN | sinecatechins | OINTMENT;TOPICAL | 021902-001 | Oct 31, 2006 | 5,968,973 | ⤷ Try for Free |
Ani Pharms | VEREGEN | sinecatechins | OINTMENT;TOPICAL | 021902-001 | Oct 31, 2006 | 5,795,911 | ⤷ Try for Free |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VEREGEN
See the table below for patents covering VEREGEN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 1185947 | ⤷ Try for Free | |
South Africa | 200403287 | MEDICAMENT FOR THE TREATMENT OF VIRAL SKIN AND TUMOUR DISEASES | ⤷ Try for Free |
Portugal | 1448186 | ⤷ Try for Free | |
European Patent Office | 2055300 | Médicament comprenant du myristate d'isopropyle et une catéchine (Medicament comprising isopropylmyristate and a catechin) | ⤷ Try for Free |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VEREGEN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1448186 | 12C0058 | France | ⤷ Try for Free | PRODUCT NAME: EXTRAIT SEC RAFFINE DE FEUILLE DE THE VERT (CAMELLIA SINENSIS (L.) O. KUNTZE) QUANTIFIE EN GALLATE D'(-)-EPIGALLOCATECHINE; NAT. REGISTRATION NO/DATE: NL41799 20120625; FIRST REGISTRATION: DE - 73186.00.00 20090831 |
1448186 | CA 2012 00040 | Denmark | ⤷ Try for Free | |
2055300 | 132016000077885 | Italy | ⤷ Try for Free | PRODUCT NAME: ESTRATTO SECCO DI CAMELLIA SINENSIS (L.) O. KUNTZE FOLIUM (TE VERDE FOGLIE) CORRISPONDENTE A (-) - EPIGALLOCATECHINA GALLATO(VEREGEN 10% UNGUENTO); AUTHORISATION NUMBER(S) AND DATE(S): 043866019 - 43866021, 20150928;73486.00.00, 20090907 |
1448186 | 29/2010 | Austria | ⤷ Try for Free | PRODUCT NAME: "(-)-EPIGALLOCATECHIN GALLAT MIT ISOPROPYLMYRISTAT"; NAT. REGISTRATION NO/DATE: 1-29000 20100217; FIRST REGISTRATION: DE 73486.00.00 (MITTEILUNG) 20090908 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for the Drug: Veregen
More… ↓